
|Articles|February 4, 2022
AJMC® in the Press, February 4, 2022
Author(s)AJMC Staff
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
An article by
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
2
Amid SOHO Data, Reviewers of BTK Inhibitors in MCL Call for Trials
3
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
4
Counseling Vitiligo Patients on Time to Repigmentation
5




